NICE may be 20 this year, but its policy on end-of-life (EoL) treatments – where NICE can recommend a treatment at around £50,000 per Quality Adjusted Life Year (QALY) – is a young policy i
Roche has beaten market expectations in third quarter results, with new drugs gaining traction and its older medicines faring better than expected against cheaper biosimilar rivals.
LA-based biotech ImaginAb has signed a multi-party agreement with pharma giants AstraZeneca, Pfizer, and Takeda, for technology that allows scientists to see inside tumours, and monitor whe
